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Background: The incidence of cystic fibrosis (CF) is low in the isolated Finnish population and the Finnish CF mutation spectrum has
differed from many European countries.
Methods: We have analyzed the mutation spectrum and the geographical distribution of CF mutations in Finland covering the last 18 years
(1987–2004).
Results: A total of 14 mutations were identified; two of them new, 774insT and S589T (G>C at 1898). The overall coverage of mutations
was 97% (99 /102 chromosomes). The most frequent mutations were F508del and 394delTT, found in 36% (37 /102) and 35% (36 /102) of
the CF chromosomes respectively. Of the rare mutations, a mutation of presumable Slavic origin, CFTRdele2.3 (21 kb), was enriched in a
rural isolate with a frequency of 5,9% (6 /102), and a mutation that possibly indicates Swedish influence, 3659delC, was scattered throughout
the country with a similar frequency of 5,9% (6/102). G542X, R1162X, R117H, 3732delA, 1898+3A>C, S1196X, S945L, W57R, 774insT
and S589T were each identified in a number of chromosomes from one to three.
Conclusions: Our observations of the Finnish CF mutation spectrum fit well with the characteristics of Finland as a population of multiple
local founder effects.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; CFTR; Mutation; Finland1. Introduction
The incidence of cystic fibrosis (CF) in Finland, 1 :25
000, is almost tenfold lower than in most European
populations. CF is caused by mutations in the gene coding
for the cystic fibrosis transmembrane conductance regulator
(CFTR; MIM# 602421), [1] a chloride channel expressed at
the membrane of epithelial cells. More than 1300 different1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
doi:10.1016/j.jcf.2005.06.002
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E-mail address: irma.jarvela@hus.fi (I. Ja¨rvela¨).mutations in the CFTR protein have been identified world-
wide [2]. The most common mutation, F508del
(c.1520_1522delTCT, p.Phe508del), ranges from less than
50% to almost 90% in European CF chromosomes. In the
countries near the Baltic Sea (Finland, Sweden, Norway,
Denmark, Estonia, Russia) the FNordic mutation_ 394delTT
(c.262_263delTT, p.Leu88fs) is also found at relatively high
frequencies [3]. The mutation has been suggested to have
originated in this area, based on haplotype associations [4].
The spectrum of the CFTR mutations in Finland has
differed from many European countries [5–7]. The major
CFTR-mutation F508del was found only in 45% and
394delTT for 30% of the CFTR chromosomes in Finland.4 (2005) 233 – 237ed by Elsevier B.V. All rights reserved.
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and 3732delA (c.3600delA, p.Asp1201fs), were each
identified in one CF chromosome out of 40. That time
20% (8 /40) of Finnish CF mutations remained unidentified.
The exceptional distribution of the mutations can be
explained by founder effect, genetic drift and national
isolation of the Finnish population. The unusually low
frequency of F508del explains the rarity of CF in Finland
and also makes other mutations appear more prevalent in
relative terms. Thus the relative portion of 394delTT in CF
chromosomes is larger in Finland than in other Nordic
countries, but the absolute prevalence in the above countries
is similar. The geographical distribution of the major
mutations showed that F508del is most prominent in areas
of old and dense settlement and 394delTT is enriched in rural
isolates in areas of relatively young settlement.
The objective of our study was to reassess the CFTR
mutation spectrum in Finland by combining the data
collected during the last 18 years from Finnish CF patients.2. Materials and methods
We studied 51 unrelated Finnish patients with clinically
confirmed or suspected diagnosis of CF. These include all
the CF patients in Finland from the 18 year period from the
year 1987 to 2004. 31 patients were new, whereas 20
patients had been analyzed earlier [7]. From the 20 patients,
8 carried an unidentified mutation. They were reanalyzed in
this study, together with the new patients.
The initial mutation screening was done by PCR and
reverse-hybridization technique; using Inno-Lipa CFTR17+
Tn Update and CFTR19 test strips (Innogenetics, Gent,
Belgium). The InnoLipa assay recognizes 36 mutations:
E60X (c.178G>T, p.Glu60X), G85E (c.254G>A, p.Gly85-
Glu), 394delTT, R117H (c.350G>A, p.Arg117His), I148T
(c.443T>C, p.Ile148Thr), 621+1G>T (c.489+1G>T),
711+1G>T (c.579+1G>T), 711+5G>A (c.579+5G>A),
1078delT (c.948delT, p.Phe316fs), R334W (c.1000C>T,
p.Arg334Trp), R347P (c.1040G>C, p.Arg347Pro), A455E
(c.1364C>A, p.Ala455Glu), I507del (c.1519_1521delATC,
p.Ile507del), F508del, 17171G>A (c.15851G>A),
G542X, G551D (c.1652G>A, p.Gly551Asp), Q552X
(c.1654C > T, p.Gln552X), R553X (c.1657C > T,
p.Arg553X), R560T (1679G>vC, p.Arg560Thr), 1898+
1G > A (c.1766 + 1G > A), 2143delT (c.2012delT,
p.Leu671fs), 2183AA>G (c.2051_2052delAAinsG,
p.Lys684fs), 2184delA (c.2052delA, p.Lys684fs), 2789+
5G>A (c.2657+5G>A), 3120+1G>A (c.2988+1G>A),
3199del6 (c.3067_3072del, p.Ile1023_Val1024del), 3272
26A >G (c.314026A >G), R1162X (c.3484C > T,
p.Arg1162X), 3849+10kbCYT, 3659delC (c.3528delC,
p.Lys1177fs), S1251N (c.3752G>A, p.Ser1251Asn),
3905insT (c.3773dupT, p.Leu1258fs), W1282X (c.3846G>
A, p.Trp1282X), N1303K (c.3909C>G, p.Asn1303Lys),
CFTRdele2,3(21kb) and Tn-polymorphism on intron 8.The samples that carried a mutation that remained
unidentified after the InnoLipa assay were analyzed further.
The whole coding region and intronic boundaries of the
CFTR gene were analyzed using multiplex denaturing
gradient gel electrophoresis (DGGE) and single-strand
conformation polymorphism analysis (SSCP/Heteroduplex)
(Genephor, Amersham Pharmacia Biotech, Buckingham-
shire, UK). The fragments with an abnormal migration
pattern were characterized by sequencing using the BigDye
Terminator Cycle Sequencing kit (PE Applied Biosystems,
Foster City, CA) on an ABI 377 sequencer.
Microsatellites IVS8CA and IVS17bTAwere analyzed as
previously described [8]. Primers were fluorescent end-
labeled and analyzed with the Applied Biosystems 672
Genescanner system.
The geographical distribution of the mutations was
studied by linking each mutation to the University hospital
districts where the patient had been diagnosed.
The CFTR cDNA sequence (GenBank NM_000492.2) is
used as the reference sequence. Traditional nucleotide
numbering starts from the beginning of the transcript, but
current recommendations suggest numbering the A of the
translation initiation codon as +1. We use traditional CFTR
mutation nomenclature, but the recommended mutation
names are also given in parenthesis upon first mention of
the mutations. Both the nucleotide and protein designations
are given, when appropriate. The current recommended
nomenclature follows Human Genome Variation Society
(HGVS) guidelines (http://www.hgvs.org/mutnomen/).3. Results
3.1. Mutation frequencies
A total of 14 mutations were found in 99/102 (97%) of
affected chromosomes in CFTR in the isolated Finnish
population (Table 1). Two of them, 774insT (c.642_
643insT, p.Ile215fs) in exon 6a and S589T (c.1766G>C,
p.Ser589Thr) in exon 12, have not been previously
described.
The most prevalent mutations were F508del and
394delTT, that together accounted for 72% (73 /102) of
the Finnish CF chromosomes. The frequency of F508del
was 36% (37 /102) in this study. This figure is even lower
than previously observed (45%, 18 /40; [7]). The frequency
of 394delTT was 35% (36 /102) compared to 30% (12 /40).
The main mutations F508del and 394delTT had a geo-
graphical distribution that was similar to previous observa-
tions. Ten other mutations were also identified (Table 1),
eight of them never found in Finland before. One of these
seven mutations, CFTRdele2,3 (21 kb), was enriched in a
rural isolate. 3659delC, on the other hand, was found in
small numbers throughout the country and could be a sign
of Swedish influence in the CFTR mutation spectrum in
Finland.
Table 1
Spectrum of CFTR mutations in Finland
Mutation Recommended nomenclature/nucleotide Recommended nomenclature/protein Exon/Intron N %
F508del c.1520_1522delTCT p.Phe508del E 10 37 36
394delTT c.262_263delTT p.Leu88fs E 3 36 35
CFTRdele2,3(21kb) E2 and E3 6 5.9
3659delC c.3528delC p.Lys1177fs E 19 6 5.9
1898+3A>C c.1766+3A>C I 12 3 2.9
R117H c.350G>A p.Arg117His E 4 2 2
S945L c.2834C>T p.Ser945Leu E 15 2 2
W57R c.169T>C p.Trp57Arg E 3 1 1
774insT c.642_643insT p.Ile215fs E 6a 1 1
G542X c.1624G>T p.Gly542X E 11 1 1
S589T c.1766G>C p.Ser589Thr E 12 1 1
R1162X c.3484C>T p.Arg1162X E 19 1 1
S1196X c.3587C>G p.Ser1196X E 19 1 1
3732delA c.3600delA p.Asp1201fs E 19 1 1
Unknown 3 2.9
Total 102 100
Reference sequence is Genbank NM_000492.2.
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The geographical distribution is summarized in Fig. 1.
The two novel mutations originate from the early settlement
region from Southern and Western Finland.
F508del was most prevalent in the university hospital
districts of Turku, Helsinki and Tampere. On the contrary
the mutation 394delTT was more prevalent in the university
hospital districts of Kuopio and Oulu. Three out of six
CFTRdele2,3(21 kb) mutations were enriched in a rural
isolate in an area overlapping with both the Oulu and
Tampere university hospital districts [7]. 3659delC was
more evenly distributed in Finland, with one or two
mutation chromosomes in each university hospital district.
The three 1898+3A>C (c.1766+3A>C) mutations were
situated in the most southern university hospital districts:
Helsinki, Tampere and Turku. Both of the R117H
mutations were situated in Northern Finland. The other
mutations that were present in only one or two chromo-
somes were situated randomly.
3.3. Novel mutations 774insT and S589T
A novel mutation, 744insT, was discovered in exon 6a of
the CFTR gene. The mutation is an insertion of a thymine
after nucleotide 774 (recommended numbering 642), and it
results in a frameshift and a premature stop codon. The
CFTR gene with 744insT mutation is expected to produce a
severely truncated protein and thus barely functional CFTR
chloride channel. 744insT was found in one chromosome
out of the 102 chromosomes studied. The patient with
774insT carried 394delTT on the other chromosome and had
a classical CF-phenotype. The patient originates from the
early settlement region, Southwestern Finland.
The second novel mutation, S589T, was found in exon
12. The mutation is a transversion of a guanine to a cytosine
at nucleotide 1898 (nucleotide 1766 on recommendednumbering). The 1898 G is the last nucleotide at the 3V
end of exon 12. We speculate that the mutation could be
disease causing by two mechanisms. First, the substitution
of serine by threonine may prevent the correct folding or
function of CFTR chloride channel. Secondly, the
1898G>C transversion may also lead to inappropriate
splicing since it disrupts the consensus splice donor site at
the 3V end of exon 12. Other mutations have also been
reported to be caused by a mutation of a G in the last
position of an exon, for example 1341G>A (c.1209G>A)
at exon 8 [9]. The patient with S589T had F508del on the
other chromosome and the phenotype was pancreatic
sufficient without meconium ileus. The ancestors of the
mutation chromosome were from Western Finland, close to
the sea [7].4. Discussion
The Finns have their own disease heritage that has been
explained by the national isolation of the Finnish population
and the regional isolation within the sparsely inhabited
country [10]. Some recessive disorders belonging to the
Finnish disease heritage are more common in Finland than
in other Caucasian populations. CF forms a low incidence
counterpart to these diseases. In this study, the frequency of
the most prevalent mutation F508del was 36%, compared to
the earlier estimate of 45%. This suggests that F508del is
even rarer in Finland than previously thought. The
frequency of 394delTT was slightly higher than previously
observed (35% vs. 30%). The geographical distribution of
the two most prevalent mutations F508del and 394delTT
were similar to previous observations. F508del was most
prevalent in areas of old and dense settlement in the
University hospital districts of Helsinki, Turku and Tam-
pere, which resemble most closely the genetic make-up of
the early Finns. 394delTT has been suggested to have a
Fig. 1. The geographical distribution of CFTR mutations in Finland by university hospital districts. The radius of the pie chart is proportional to the total
population in each district (population information from the year 2002 from the Association of Finnish Local and Regional Authorities: http://
www.localfinland.fi). The total number of CF alleles in each district is presented in the center of the pie chart.
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and enriched in rural isolates. The unusually high preva-
lence of 394delTT in Oulu and Kuopio regions, which are
areas of relatively young settlement, further supports this
hypothesis.
The third most prevalent mutations in Finland were
3659delC and CFTRdele2,3(21 kbdel). 3659delC was found
in 5,9% (6 /102) of the CF chromosomes. The mutation is
found frequently in Sweden [3]. In a study that comprised
75% of the Swedish CF population, the mutation was found
in 7,9% of the CF chromosomes [11]. The even geo-
graphical distribution of 3659delC in Finland suggests that
it is possible that the mutation is not new in Finland and that
it may have come to Finland by the slow but continuous
importation of genes from Sweden.
Three out of the six CFTRdele2,3(21 kb) mutations
were enriched in a rural isolate on the west coast of
Finland. The existence of the cluster had already been
hypothesized based on haplotype analysis and genealogical
data [7], but the mutation had remained unidentified.
Interestingly, CFTRdele2,3(21 kb) is a mutation of Slavic
origin, associated with a severe phenotype [12]. Wehypothesize that the CFTRdele2,3(21 kb) mutation may
have been imported to Finland from Central or Eastern
Europe, where the mutation is common [12]. This hypoth-
esis is further supported by the fact that five Finnish
CFTRdele2,3(21 kb) chromosomes carried the same infre-
quent intragenic microsatellite haplotype 16-33 (IVS8CA-
IVS17bTA), that has been detected in all chromosomes with
CFTRdele2,3(21 kb) so far [12].
Nine mutations were found in Finland with a relative
frequency equal or smaller than 2%. Most of these
mutations appear to be rare throughout the world. An
exception is G542X, which is one of the five mutations that
have relative world frequencies higher than 1%. It has been
suggested to have a Phoenician origin [13], and it is present
in most European countries with the highest mean
frequency in the Mediterranean area (6,1%) [3]. Some
other rare mutations that were detected in Finland also
reach relatively high frequencies in specific areas:
3732delA in Russia; R117H in Norway and in the Celtic
countries; R1162X in Northern Italy (although multi-
ethnicity and recurrence has been demonstrated for this
mutation) [3,14].
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found in the coastal areas of Finland that have traditionally
had most connections to the neighboring countries and are
genetically most mixed. Thus the new mutations may be
imported, although we cannot exclude the possibility that
they are de novo mutations.
There were three patients with a mutation that remained
unidentified. One of the patients carried F508del on the
other chromosome and had strong evidence for the
diagnosis of CF: pathological sweat test, malabsorbtion
and malnutrition. The other two patients were both from
northern Finland and carried R117H on the other chromo-
some. Both R117H mutations were in combination with 7T
variant on the T-tract of intron 8. The phenotypes of both of
these patients were of a less classical form. It is possible that
the three patients with only one CFTR mutation identified
might represent a CFTR related phenotype, or they might
have a large deletion or an intronic mutation that remained
unidentified.
14 mutations explain 97% of CF mutations in Finland.
The heterogeneity of Finnish CFTR mutations is relatively
small when compared to for example in Spain, where 75
mutations explain 90% of CFTR mutations [15]. This
observation fits well with the characteristics of Finland as
a population of multiple local founder effects. The results of
our study are of evident interest for clinical testing of Cystic
Fibrosis in Finland.Acknowledgments
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